| Followers | 679 |
| Posts | 141164 |
| Boards Moderated | 36 |
| Alias Born | 03/10/2004 |
Friday, July 16, 2021 8:15:42 AM
Moderna (MRNA) Added to S&P 500 as Vaccine Maker Surges to Record High
By: TheStreet | July 15, 2021
• Moderna will replace Alexion Pharmaceuticals in the S&P 500 benchmark following that group's $39 billion takeover by Britain's AstraZeneca in December of last year.
Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.
Moderna will replace Alexion Pharmaceuticals (ALXN) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its $39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.
Moderna shares were marked 7.8% higher in pre-market trading Friday to indicate an opening bell price of $280.00 each, an all-time high that would extend the stock's year-to-date gain to around 168% with a market value of around $112 billion.
Moderna posted stronger-than-expected first quarter earnings of $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.
Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of "working hard to get as close to 1 billion doses in 2021 as we can," Bancel said in early May.
"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021."
Last month, the group formally asked the U.S. Food & Drug Administration for emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.
Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study "met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.
The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.
Read Full Story »»»
DiscoverGold
By: TheStreet | July 15, 2021
• Moderna will replace Alexion Pharmaceuticals in the S&P 500 benchmark following that group's $39 billion takeover by Britain's AstraZeneca in December of last year.
Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.
Moderna will replace Alexion Pharmaceuticals (ALXN) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its $39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.
Moderna shares were marked 7.8% higher in pre-market trading Friday to indicate an opening bell price of $280.00 each, an all-time high that would extend the stock's year-to-date gain to around 168% with a market value of around $112 billion.
Moderna posted stronger-than-expected first quarter earnings of $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.
Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of "working hard to get as close to 1 billion doses in 2021 as we can," Bancel said in early May.
"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021."
Last month, the group formally asked the U.S. Food & Drug Administration for emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.
Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study "met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.
The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.
Read Full Story »»»
DiscoverGold
Information posted to this board is not meant to suggest any specific action, but to point out the technical signs that can help our readers make their own specific decisions. Caveat emptor!
• DiscoverGold
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
